This study aims to assess the safety and effectiveness of telemedicine guided strategy on guideline-directed medical therapy (GDMT) optimization in hospitalized patients with heart failure in comparison to usual care in Switzerland.
Heart failure (HF) is a chronic condition affecting approximately 26 million people worldwide, with acute decompensations leading to frequent hospitalizations and increased mortality. While guideline-directed medical therapy (GDMT) has been shown to improve outcomes in HF with reduced ejection fraction (HFrEF), real-world data indicate suboptimal implementation, with delayed initiation and low adherence to target doses. The STRONG-HF study demonstrated that rapid up-titration of GDMT following hospitalization significantly reduces HF-related mortality and readmission, highlighting the importance of early and structured treatment optimization. However, close monitoring during the vulnerable post-discharge phase remains resource-intensive and difficult to implement in routine care. The DIGNITY study aims to assess the safety and effectiveness of a telemedicine-guided strategy for optimizing GDMT in patients with HFrEF compared to usual care in Switzerland after discharge. The study hypothesizes that telemedicine-supported management will improve GDMT optimization and clinical outcomes in this high-risk patient population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
140
Patients in the "usual care group" will be followed up according to the local practice until the end of the study.
Patients are followed via an App, data will be evaluated by the Telemedicine team, and participants will be contacted via phone 1 week after discharge and subsequently every 7-10 days to discuss the up-titration of the HF medications.
University Hospital Basel
Basel, Switzerland
RECRUITINGcomposite guideline-directed medical therapy optimization score
composite guideline-directed medical therapy (GDMT) score is defined as the sum of care optimization changes and care deoptimization changes at 3 months post discharge.
Time frame: 3 month post-discharge
Proportion of clinical encounters setting 1
Proportion of clinical encounters with GDMT initiations when these therapies were not used at discharge
Time frame: during whole study phase from randomization to 90 days post-discharge
Proportion of clinical encounters setting 2
Proportion of clinical encounters with either GDMT initiations and/ or dose uptitrations, net GDMT intensification and changes in the prescription of individual GDMT elements from time to hospital admission to discharge
Time frame: during whole study phase from randomization to 90 days post-discharge
Dosage of diuretics
Requirement for decreasing or increasing dose of diuretics
Time frame: during whole study phase from randomization to 90 days post-discharge
Proportion of safety issues
Safety outcomes including incidence of hypotension, hyperkalemia, acute kidney failure (doubling of baseline serum creatinine)
Time frame: during whole study phase from randomization to 90 days post-discharge
Proportion of heart failure
Re-hospitalization due to heart failure decompensation
Time frame: during whole study phase from randomization to 90 days post-discharge
Proportion of hospitalization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
All-cause re-hospitalization
Time frame: during whole study phase from randomization to 90 days post-discharge
Quality of life score
Quality of life (Kansas City Cardiomyopathy Questionnaire (KCCQ).
Time frame: at randomization and 90 days post-discharge
Optimization score
Optimization score is defined as the sum of care optimization changes and care deoptimization changes.
Time frame: at randomization and 90 days post-discharge
Patient Health Questionnaire
The Patient Health Questionnaire (PHQ-2) measures the frequency of depressed mood, with a score ranging from 0 to 6.
Time frame: at randomization and 90 days post-discharge